AbbVie Highlights Innovative Research From Its Rheumatology

ABBVie today announced the presentation of new data on RINVOQ ® SKYRIZI ® and HUMIRA ® across multiple rheumatic diseases at the American College of Rheumatology's annual meeting to be held virtually Nov. 3-9 . A total of 38 abstracts, including two oral presentations and one plenary session presentation, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing ...

Related Keywords

United States , Ohio , Turkey , Upadacitinib Monotherapy , Brandee Pappalardo , Instagram , Linkedin , American College Of Rheumatology , Rheumatology Patient Research Registry , Allergan , Abbvie Inc , Facebook , Drug Administration , Association Between Clinically Meaningful Improvements In Patient , European Commission , Group Analysis , Association Between Clinically Meaningful Back Pain Improvement , Laboratory Abnormality Profiles Of Upadacitinib , Exchange Commission , Youtube , American College , Term Safety , Rheumatoid Arthritis , Combination Therapy , Across Patient Populations , Response Between Upadacitinib , Results Through , Serologic Status , Clinical Responses , Prior Inadequate Response , Sub Group Analysis , Patient Index Data , Rheumatoid Arthritis Treated , Long Term Upadacitinib Therapy , Driven Dissection , Inflammation Modulatory Effects , Active Rheumatoid Arthritis Refractory , Protein Biomarkers , Inadequate Responders , Active Rheumatoid Arthritis , Laboratory Abnormality Profiles , Term Efficacy , Upadacitinib Among Patients , Biological Disease Modifying Anti Rheumatic Drugs , Active Psoriatic Arthritis , Week Results , Double Blind Clinical Trial , Observational Study , Psoriatic Arthritis , Early Pain Improvement , Patient Reported Outcomes , Week Integrated Results From , Double Blind Clinical Trials , Treatment Experience , Patient Preferences , Disease Burden , Achieving Minimal Disease Activity , Patient Reported Outcome Measures , Disease Activity Among Patients , Psoriatic Arthritis Treated , Targeted Synthetic , Between Clinically Meaningful Improvements , Stringent Measures , Disease Activity , Axial Involvement Defined , Investigator Assessment , Based Criteria , Two Phase , Ankylosing Spondylitis , Baseline Demographics , Disease Activity Measures , Ankylosing Spondylitis Receiving Upadacitinib , Post Hoc Subgroup Analysis , Active Ankylosing Spondylitis , Year Results , Placebo Controlled Study , Open Label Extension , Post Hoc Analysis , Term Safety Profile , Peripheral Manifestations , Upadacitinib Clinical Trials , Safety Information , Important Safety Information , Mississippi River , Full Prescribing Information , Medication Guide , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , North Chicago , Endoscopic Remission , Subjects With Moderately , Severely Active Crohn , Disease Who Have Inadequately Responded , Are Intolerant , Maintenance Therapy , Severely Active Ulcerative , Study Evaluating , Subjects With Active Ankylosing Spondylitis , Participants With Giant Cell Arteritis , Study Comparing Upadacitinib , Inadequate Response , Compare Safety , Adult Participants With Moderate , Severe Atopic Dermatitis , Evaluate Efficacy , Adult Participants With Axial Spondyloarthritis , Subjects With Takayasu Arteritis , Participants With Psoriatic Arthritis Who Have ,